8-K/A filed September 16, 2025, 7:59 PM ET ticker PTHS CIK 0001919246

other material confidence high sentiment neutral materiality 0.75

Pelthos Therapeutics Inc. (PTHS): M&A transaction — Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025

Pelthos Therapeutics Inc.

Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.
ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.
Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.
Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Pelthos Therapeutics Inc. completed an acquisition involving LNHC, Inc. and Ligand Pharmaceuticals Incorporated (closed 2025-07-01).

Action: acquisition
Counterparty: LNHC, Inc. and Ligand Pharmaceuticals Incorporated
Closing: 2025-07-01

Exact text from the filing

On July 1, 2025, Channel Therapeutics Corporation, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand consummated the Merger

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001753926-25-001500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.